ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Phospho-Histone H3 as a Tool for Improved Mitotic Counting and Risk Assessment in Gastrointestinal Stromal Tumors: A Study of 241 Cases.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Cell mitotic count is a core indicator for risk stratification (RS) in gastrointestinal stromal tumors (GIST). Studies have shown that phospho-histone H3 (PHH3) can specifically recognize mitotic figures, but the consistency of this method with the traditional hematoxylin-eosin (HE) method, the consistency among different observers, and the counting efficiency remain unclear. This study aimed to evaluate risk stratification in 241 patients with GIST using the cell proliferation marker PHH3 and cell mitosis counts. MATERIAL AND METHODS We collected data from 241 patients with GIST who underwent radical surgical resection. Specimens were stained with HE and PHH3 immunohistochemistry. Three pathologists conducted the mitotic count on HE (MC-HE) and the mitotic count on PHH3 (MC-PHH3) in 5-mm² areas of tumor "hotspots" under blinded conditions. The counting results, consistency of RS, counting time, and inter-observer differences were compared, and the correlation with clinical and pathological parameters was analyzed. RESULTS There was a strong correlation between MC-PHH3 and MC-HE (r=0.879, P<0.01). The consistency rate of RS based on MC-PHH3 was 95%, with 8 cases upgraded and 4 cases downgraded. The average counting time of MC-PHH3 was significantly shorter than that of MC-HE (P<0.05). In terms of inter-observer consistency, the intra-class correlation coefficient of MC-PHH3 was 0.710, higher than the 0.648 of MC-HE. Both counting methods were significantly correlated with tumor size, whether it was ruptured, RS, and necrosis (P<0.05). CONCLUSIONS PHH3 serves as a valuable adjunct to enhance the reliability and efficiency of pathological assessment in GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.